Press release
Roxadustat Market Size Projected To Reach 9.15 Billion By 2034 With A Cagr Of 7.3%
Roxadustat
What Is the Projected Growth of the Roxadustat Market?
Over the past few years, the Roxadustat market has exhibited robust growth. It is projected to rise from $6.44 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. Factors such as regulatory green signals in key markets, positive outcomes from clinical trials, a greater incidence of chronic kidney disease, heightened awareness about anemia management, and government backing for anemia therapies have conveyed this increase during the historical period.
Strong expansion in the Roxadustat market size is anticipated in the upcoming years, reaching a valuation of $9.16 billion in 2029, with a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the growth during this forecast period include continued studies around new indications, a rise in healthcare spendings, need for anemia treatments that don't require injections, wider reimbursement policies, and an increase in the elderly population. The observing trends throughout the forecast period encompass a move towards oral treatments for anemia, rising competitions from other therapeutic methods, the broadening of licensing agreements, increasing funding in research on hypoxia-inducible factors, and a shift towards treatments that are more focused on the patient.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280
What Are the Different Roxadustat Market Segments?
The roxadustat market covered in this report is segmented -
1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions
Subsegments:
1) By 20mg: Oral Tablets, Injectable Formulations
2) By 50mg: Oral Tablets, Injectable Formulations
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp
What Are the Primary Drivers Shaping the Roxadustat Market?
The escalating figures of individuals afflicted by chronic kidney disease (CKD) are projected to drive the expansion of the Roxadustat market. CKD is a long-term ailment that results in a step-by-step loss of kidney function, which, without treatment, can escalate into kidney failure. The global increase in CKD patients can be attributed to numerous factors such as an aging population, rising diabetes and hypertension rates, and poor lifestyle choices. Roxadustat acts as a management tool for CKD, as it stimulates the production of erythropoietin, elevating the production of red blood cells and addressing the often conjoined issue of anemia. This ultimately improves kidney function and enhances quality of life for patients. To illustrate, as per a December 2024 report from the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, there was a moderate annual increase in mortality rates due to CKD, with a 4.2% rise documented in 2021 and a 6.2% increase in 2022. This trend of escalating CKD cases globally is hence fueling the expansion of the Roxadustat market.
Which Companies Are Leading in the Roxadustat Market?
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.
What Are the Major Trends Shaping the Roxadustat Market?
In the Roxadustat market, key players are pursuing reimbursement via the high-tech drugs scheme. This strategy aims to increase patient availability by lessening financial constraints, consequently boosting market adoption and showcasing the cost-efficiency of their pioneering therapies. Specifically controlled in Ireland, this high-tech drugs scheme offers reimbursement for the provision of costly, highly specific medications generally prescribed in hospital situations. For example, Astellas Pharma Company Ltd., an American pharmaceutical company, disclosed in September 2022 that their product EVRENZO (Roxadustat), had earned reimbursement under Ireland's High-Tech Drugs Scheme. Roxadustat is the premier drug of its kind, an orally taken hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor, that is both licensed and reimbursed in Ireland. It has proven effective in reaching and upholding designated hemoglobin quantities (10-12g/dL) in patients suffering from symptomatic anemia of CKD, irrespective of dialysis condition and former ESA treatments.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report
What Are the Top Revenue-Generating Geographies in the Roxadustat Market?
North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Roxadustat Market?
2. What is the CAGR expected in the Roxadustat Market?
3. What Are the Key Innovations Transforming the Roxadustat Industry?
4. Which Region Is Leading the Roxadustat Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.
Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Roxadustat Market Size Projected To Reach 9.15 Billion By 2034 With A Cagr Of 7.3% here
News-ID: 4069749 • Views: …
More Releases from The Business Research Company
Impact Of Rising Infrastructure Investment On The Market Growth Due To Increasin …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Hydrophilic Swelling Waterstop Market Through 2025?
In recent times, there has been robust growth in the hydrophilic swelling waterstop market size. It is expected to mature from a value of $0.87 billion in 2024 to $0.94 billion in 2025, illustrating a compound…
Emerging Trends to Drive Hot Melt Waterproofing System Market Growth at 7% CAGR …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hot Melt Waterproofing System Market Size Growth Forecast: What to Expect by 2025?
There has been a substantial expansion in the hot melt waterproofing system market in the last few years. It is projected to rise from $2.34 billion in 2024 to $2.52 billion in 2025, with a compound…
High-Pressure Blasting Service Market: Major Trends Reshaping the Future of the …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the High-Pressure Blasting Service Industry Market Size Be by 2025?
The market size for high pressure blasting services has seen substantial growth in the past few years. The market, which is predicted to rise from a value of $3.18 billion in 2024 to $3.40 billion in 2025,…
Impact Of Rising Construction Activities On The Market Growth Due To Increasing …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
High Performance Plasterboard Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the last few years, there has been a robust expansion of the high performance plasterboard market size. It's predicted to increase from $13.32 billion in 2024 to $14.21 billion in 2025, showcasing a…
More Releases for Roxadustat
Roxadustat Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, S …
" As of 2024, the global Roxadustat market is valued at approximately $1.1 billion, driven by increasing demand for innovative therapies to treat anemia, particularly in patients with chronic kidney disease (CKD). The market is projected to grow to around $3.2 billion by 2034, reflecting a robust expansion fueled by an aging population, escalating CKD prevalence, and ongoing clinical research into Roxadustat's efficacy."
Exactitude Consultancy., Ltd. released a research report titled…
Roxadustat Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, S …
" As of 2024, the global Roxadustat market is valued at approximately $1.1 billion, driven by increasing demand for innovative therapies to treat anemia, particularly in patients with chronic kidney disease (CKD). The market is projected to grow to around $3.2 billion by 2034, reflecting a robust expansion fueled by an aging population, escalating CKD prevalence, and ongoing clinical research into Roxadustat's efficacy."
Exactitude Consultancy., Ltd. released a research report titled…
In-Depth Analysis of the Roxadustat Market: Growth Opportunities, Key Trends, an …
What industry-specific factors are fueling the growth of the roxadustat market?
The growing number of individuals with chronic kidney disease (CKD) is expected to drive the growth of the Roxadustat market. CKD is a long-term condition in which the kidneys progressively lose their ability to function properly, potentially leading to kidney failure if untreated. The rising number of CKD patients globally is attributed to factors such as aging populations, increased rates…
Chemotherapy Induced Anemia Market Forecast 2032: FDA, EMA, PDMA Approvals, Clin …
Chemotherapy Induced Anemia companies are Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5…
Chemotherapy Induced Anemia Pipeline Analysis (2023) Covering Clinical Trials, E …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are actively developing novel therapies in the Chemotherapy Induced Anemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy Induced Anemia Pipeline Insight, 2023" report…
Roxadustat API Market Size, Growth, Trends, Share & Forecast 2023-2029|
Los Angeles, United States,- The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Roxadustat API market. It sheds light on how the global Roxadustat API market is expected to grow during the course of the forecast period. With SWOT analysis and Porter's Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global Roxadustat API…
